One way in which cancer cells flourish is by concealing themselves against cytotoxic immune cells.

Immunogenetics: Open access journal focuses on the genetic research areas of autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, Crohn’s disease, diabetes mellitus type 1, systemic lupus erythematous, etc. Articles on genetics of cell interaction with immune system, immune response to transplantation, immune based therapies for treatment of cancers, antigenic phylogeny of alleles, alloantigens are also welcome.

Contributors are welcome to publish high quality clinical, and laboratory research as case series, reviews, guidelines, techniques and practices.

It is basically aimed at the medical/ health practitioners, students, professionals and researchers and professional bodies and institutions.

Increasing the number of iNKT cells, therefore, could be an effective cell therapy against cancers. These cells come from patient iNKT cells that were reprogrammed to iPS cells and then multiplied before being differentiated to re-iNKT cells, thus significantly increasing the number of iNKT cells from before.

Unexpectedly, although the re-iNKT cells behaved like iNKT cells, they showed properties that deviated from their origin and resulted in more potency. These deviations suggest that re-iNKT cells followed a different development pathway than normal iNKT cells. Such an alternative pathway could open the door to the preparation of different cell types for cancer therapy. Kaneko explains, "Cancer patients usually have severely weakened immune systems. The ability to make potent immune cells is very helpful."

The creation of potent immune cells also has important implications on our understanding of how immune cells are formed. The immune system is maybe the most complicated system in the body.

The group is now investigating the different pathways in which iNKT cells can be formed and identifying which are best for cancer therapy.

Submit manuscripts on Editorial submission & Review tracking system or attachment to email at [email protected]

Contact Details
Robert Solomon
Managing Editor
Immunogenetics: open access